Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RFA for small renal tumors holds up over long term

Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045

Key clinical point: Radiofrequency ablation of small renal tumors is safe and effective.

Major finding: In 106 patients with small renal masses, disease-free survival was 89% at 6 years post procedure.

Study details: Retrospective cohort study of 106 patients with 112 tumors, followed up to 10 years.

Disclosures: The authors reported no conflicts of interest and no outside sources of funding.

Source: Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045.

Read the article.

Citation:

Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045

This Week's Must Reads

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018

Must Reads in Renal Cell Carcinoma

PFS superior with avelumab and axitinib in advanced RCC, Motzer RJ et al. ESMO 2018. Abstract LBA6_PR

Adjuvant axitinib may benefit highest risk RCC patients, Quinn DI et al. Ann Oncol. 2018 Oct 20. doi: 10.1093/annonc/mdy454

High KPNA2 signals poor outcomes for RCC, Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

RCC patient and disease characteristics differ by race/ethnicity, Batai K et al. Clin Genitourin Cancer. 2018 Oct 26. doi: 10.1016/j.clgc.2018.10.012

Change in tumor burden signals treatment needs in mRCC, Bimbatti D et al. Urol Oncol. 2018 Oct 6. doi: 10.1016/j.urolonc.2018.08.018